Ventyx Biosciences Reveals Q4 and Full-Year 2024 Financial Results, Corporate Advancements
Ventyx Biosciences: Exciting Progress in NLRP3 Inhibition with VTX2735 and VTX3232 Ventyx Biosciences, a clinical-stage biopharmaceutical company, reported its fourth quarter and full year 2024 financial results, showcasing significant strides in its pipeline and business advancements. The company, which focuses on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, is leading the way…